Patent · US Expired

Conjugate between a modified superantigen and a target-seeking compound and the use of the conjugate

US7226601B1 · kind B1 · utility

6Cited by

7References

2Claims

0Family size

Assignee

Active Biotech AB · SE

Inventors

Lars Abrahmsen · Bromma, SE
Per Bjork · Helsingborg, SE
Mikael Dohlsten · Lund, SE
Terje Kalland · Arese, IT

Key dates

Filing date	Jun 7, 1995
Grant date	Jun 5, 2007
Priority date	—
Expiry date	Jun 7, 2015

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2319/30
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

A method for the treatment of a disease in a mammal by administering a therapeutically effective amount of a conjugate comprising a biospecific affinity counterpart and a peptide, wherein the peptide contains an amino acid sequence that is derived from staphylococcal enterotoxin A, binds to a Vβ of a T cell receptor, and has a D227A mutation so that the peptide has a modified ability to bind to MHC class II antigens.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.